Diabetes
From the Journals
Metformin bombs in breast cancer in landmark trial
“Metformin is not effective against the most common types of breast cancer and any off-label use [of] this drug for the treatment of these common...
Feature
Newly approved tirzepatide’s retail price announced
The recently approved twincretin will carry a U.S. retail price similar to one of its main competitors, semaglutide, but patient discounts will be...
Commentary
Does COVID-19 raise the risk for diabetes?
Some data say yes and other data say no. Dr. Anne L. Peters sorts it out.
News
Many Americans missing an opportunity to prevent dementia
“Health care professionals should also screen patients for modifiable risk factors, counsel patients with risk factors, and refer them to...
Conference Coverage
Pancreatic involvement in COVID-19: What do we know?
“Our data identify the human pancreas as a target of SARS-CoV-2 infection and suggest that pancreatic beta cell involvement could contribute to...
From the Journals
Could new therapy for food ‘cues’ improve weight loss?
Patients highly sensitive to food ‘cues’ may benefit from behavioral therapy, but the intervention is labor intensive and tied to modest weight...
News
Tirzepatide (Mounjaro) approved for type 2 diabetes
Endocrinologists voice enthusiasm for the first approved agent for patients with type 2 diabetes that is a dual incretin agonist, but they also...
From the Journals
NAFLD vs. MAFLD: What’s in a name?
NAFLD may not be the most appropriate name because “nonalcoholic” may overemphasize the absence of alcohol, but is “metabolic associated” any...
Conference Coverage
First fatty liver guidelines for endocrinology, primary care
Endocrinologists and primary care docs “need to be the ones who are diagnosing and managing [non-alcoholic fatty liver disease] because there just...
Conference Coverage
Exenatide linked to less hyperglycemia after stroke
The diabetes drug may offer better control than insulin for hyperglycemia, a common condition following stroke that leads to worse outcomes.
Commentary
What is the glycemic risk index and why do we need it?
Dr. Anne Peters discusses the development of the glycemic risk index, a new continuous glucose monitoring measure.